Severity of fatigue in people with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis - Results of a cross-sectional study.
Adult
Arthritis, Psoriatic
/ complications
Arthritis, Rheumatoid
/ complications
Cross-Sectional Studies
Denmark
/ epidemiology
Fatigue
/ epidemiology
Female
Humans
Male
Middle Aged
Patient Reported Outcome Measures
Severity of Illness Index
Socioeconomic Factors
Spondylarthritis
/ complications
Surveys and Questionnaires
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
03
2019
accepted:
10
06
2019
entrez:
29
6
2019
pubmed:
30
6
2019
medline:
18
2
2020
Statut:
epublish
Résumé
Despite improvements in treatment for rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (axSpA), several key unmet needs remain, such as fatigue. The objective of this study was to describe the severity of fatigue, disease characteristics and socioeconomic factors in people with RA, PsA and axSpA. The study was designed as a cross-sectional survey collecting patient characteristics such as disease characteristics, socioeconomic factors and fatigue in people with RA, PsA and axSpA in Denmark. Respondents were consecutively recruited for the study over a six-month period in 2018 via routine visits to outpatient rheumatology clinics. Study nurses collected information on diagnosis, current disease-related treatment and disease activity from medical journals. People were invited to complete a questionnaire related to socioeconomic factors and containing the FACIT-Fatigue subscale. Descriptive statistics were analyzed using SAS. We invited 633 people to participate, and 488 (77%) completed the questionnaire. Women constituted 62% of respondents, and the mean age was 53.5 years. Respondents had on average been diagnosed between 11 and 15 years ago. Overall, 79% had no changes to their disease-related treatment during the past year, and the average disease activity as indicated by DAS28 for RA and PsA was 2.48 and 2.36, respectively, and BASDAI for axSpA was 28.40. Fatigue was present in all three diagnoses (mean: 34.31). The mean fatigue score varied from respondents answering that they suffered from no or little fatigue (mean: 45.48) to extreme fatigue (mean: 10.11). Analyses demonstrated that the respondents were not considerably different from nonrespondents, and the study population is considered representative compared with Danish RA and axSpA patients in the Danish National Rheumatology Registry, the DANBIO database. We found that the majority of the study population were fatigued (61%). They had low disease activity and few disease-related treatment changes.
Sections du résumé
BACKGROUND
Despite improvements in treatment for rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (axSpA), several key unmet needs remain, such as fatigue. The objective of this study was to describe the severity of fatigue, disease characteristics and socioeconomic factors in people with RA, PsA and axSpA.
METHODS
The study was designed as a cross-sectional survey collecting patient characteristics such as disease characteristics, socioeconomic factors and fatigue in people with RA, PsA and axSpA in Denmark. Respondents were consecutively recruited for the study over a six-month period in 2018 via routine visits to outpatient rheumatology clinics. Study nurses collected information on diagnosis, current disease-related treatment and disease activity from medical journals. People were invited to complete a questionnaire related to socioeconomic factors and containing the FACIT-Fatigue subscale. Descriptive statistics were analyzed using SAS.
RESULTS
We invited 633 people to participate, and 488 (77%) completed the questionnaire. Women constituted 62% of respondents, and the mean age was 53.5 years. Respondents had on average been diagnosed between 11 and 15 years ago. Overall, 79% had no changes to their disease-related treatment during the past year, and the average disease activity as indicated by DAS28 for RA and PsA was 2.48 and 2.36, respectively, and BASDAI for axSpA was 28.40. Fatigue was present in all three diagnoses (mean: 34.31). The mean fatigue score varied from respondents answering that they suffered from no or little fatigue (mean: 45.48) to extreme fatigue (mean: 10.11). Analyses demonstrated that the respondents were not considerably different from nonrespondents, and the study population is considered representative compared with Danish RA and axSpA patients in the Danish National Rheumatology Registry, the DANBIO database.
CONCLUSION
We found that the majority of the study population were fatigued (61%). They had low disease activity and few disease-related treatment changes.
Identifiants
pubmed: 31251785
doi: 10.1371/journal.pone.0218831
pii: PONE-D-19-06019
pmc: PMC6599141
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0218831Déclaration de conflit d'intérêts
We have read the journal's policy and the authors of this manuscript have the following competing interests: SES and HHJ report consultation fees from Pfizer Denmark during the conduct of the study and consultation fees from Pfizer Denmark outside the submitted work. SES and HHJ are employees of Incentive, which was a paid vendor of Pfizer Denmark and a commercial company. BAE is an employee of Rigshospitalet and University of Copenhagen and reports research grant for data collection and personal fees for lead investigator consultancy on the protocol development from the funder during the conduct of the study. In addition, BAE has received research grants and personal consultancy fees from the funder outside the submitted work. TP and LH are employees of Pfizer Denmark and reports salaries from Pfizer Denmark. There are no patents, products in development, or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Clin Rheumatol. 2014;33(10):1467-74
pubmed: 24322832
J Rheumatol. 2005 May;32(5):811-9
pubmed: 15868614
Rheumatol Int. 2015 Oct;35(10):1655-64
pubmed: 25947325
Mod Rheumatol. 2014 Nov;24(6):980-4
pubmed: 24884480
Rheumatology (Oxford). 2006 Jul;45(7):885-9
pubmed: 16449363
BMC Med Res Methodol. 2016 May 26;16:62
pubmed: 27387456
Arthritis Care Res (Hoboken). 2016 Sep;68(9):1320-31
pubmed: 26713432
Clin Rheumatol. 2013 May;32(5):557-66
pubmed: 23292480
J Rheumatol. 2003 Jan;30(1):167-78
pubmed: 12508408
Ann Rheum Dis. 2007 Jul;66(7):936-9
pubmed: 17324972
Arthritis Care Res (Hoboken). 2013 Jul;65(7):1128-46
pubmed: 23335492
BMC Med. 2016 Aug 20;14(1):122
pubmed: 27543008
PLoS One. 2015 Apr 08;10(4):e0123582
pubmed: 25853482
World J Orthop. 2014 Sep 18;5(4):537-43
pubmed: 25232529
Onkologie. 2003 Apr;26(2):140-4
pubmed: 12771522
Arthritis Rheum. 1980 Feb;23(2):137-45
pubmed: 7362664
Cancer. 2002 Jan 15;94(2):528-38
pubmed: 11900238
Ann Rheum Dis. 2009 Oct;68(10):1553-8
pubmed: 18930991
J Clin Nurs. 2007 Nov;16(11C):377-83
pubmed: 17931330
J Rheumatol. 1996 Aug;23(8):1407-17
pubmed: 8856621
Scand J Rheumatol. 2016 Jul;45(4):255-61
pubmed: 26690505
Rheumatology (Oxford). 2009 Mar;48(3):207-9
pubmed: 18927188
Dan Med Bull. 1973 Jun;20(3):86-93
pubmed: 4766155
Assessment. 2014 Dec;21(6):706-12
pubmed: 24986784
Joint Bone Spine. 2016 Jul;83(4):439-43
pubmed: 27055727
J Rheumatol. 2016 Apr;43(4):751-7
pubmed: 26879350
Value Health. 2018 Nov;21(11):1313-1321
pubmed: 30442279
J Rheumatol. 1995 Apr;22(4):639-43
pubmed: 7791155
J Clin Rheumatol. 2014 Mar;20(2):87-90
pubmed: 24561411
Curr Rheumatol Rep. 2017 May;19(5):25
pubmed: 28386762
Rev Bras Reumatol Engl Ed. 2017 Sep - Oct;57(5):431-437
pubmed: 28663038
Ann Rheum Dis. 2008 Oct;67(10):1422-6
pubmed: 18208866
Arthritis Rheum. 2007 Apr 15;57(3):429-39
pubmed: 17394228
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
Clin Exp Rheumatol. 2017 Jul-Aug;35(4):571-578
pubmed: 28240589
Arthritis Rheum. 1981 Oct;24(10):1308-15
pubmed: 7306232
Rheumatology (Oxford). 2011 Jun;50(6):1004-6
pubmed: 20819797
J Epidemiol Community Health. 2000 Nov;54(11):827-33
pubmed: 11027196
J Rheumatol. 2018 Nov;45(11):1515-1521
pubmed: 30173149
Joint Bone Spine. 2016 Jul;83(4):427-31
pubmed: 26709252